Glenmark Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Bonus
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Profit before tax

1,571.87

2,337.45

1,943.76

1,534.64

1,818.18

Net cashflow-operating activity

1,474.06

1,216.07

1,243.42

1,579.12

2,489.58

Net cash used in investing activity

-431.47

-896.92

-1,235.23

-1,607.38

-2,255.61

Netcash used in fin. activity

-978.50

-305.12

-80.79

-139.42

-155.11

Net inc/dec in cash and equivlnt

64.05

13.93

-72.57

-167.71

78.95

Cash and equivalnt begin of year

28.65

14.72

87.29

255.00

176.05

Cash and equivalnt end of year

92.70

28.65

14.72

87.29

255.00